Wrighton-Smith Peter 4
4 · Oxford Immunotec Global PLC · Filed Apr 3, 2019
Insider Transaction Report
Form 4
Wrighton-Smith Peter
DirectorChief Executive Officer
Transactions
- Sale
Ordinary Shares
2019-04-01$17.21/sh−600$10,326→ 434,538 total - Award
Share Option (Right to Buy)
2019-04-01+67,959→ 67,959 totalExercise: $16.42Exp: 2029-04-01→ Ordinary Shares (67,959 underlying) - Award
Ordinary Shares
2019-04-01+31,669→ 445,138 total - Sale
Ordinary Shares
2019-04-01$16.64/sh−10,000$166,446→ 435,138 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
- [F2]The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- [F3]The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- [F4]Options granted under Issuer's 2013 Share Incentive Plan
- [F5]Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2020 through January 1, 2023.